{
  "abstract": "Across solid tumors, cells of the myeloid lineage—monocytes, macrophages, dendritic cells, and granulocytes—play major roles in cancer biology by regulating immune responses, angiogenesis, tumor cell invasion and metastasis, and treatment outcomes. These cells arise from multiple ontogenies, are highly adaptable to tissue cues, cancer-associated inflammation, obesity, and aging, with vast transcriptional diversity that reflects functional heterogeneity. Although the majority of myeloid subsets limit durable anticancer responses, populations with antitumor activity are also documented. This profound heterogeneity underscores the need for a deep understanding of myeloid functional states to define which populations should—and should not—be targeted therapeutically.",
  "authors": [
    {
      "affiliations": [
        "Surgery, Brigham and Women’s Hospital, Boston, Massachusetts, USA",
        "Harvard Medical School, Boston, Massachusetts, USA"
      ],
      "name": "Jennifer L Guerriero"
    },
    {
      "affiliations": [
        "ICC, Early Oncology, AstraZeneca, Gaithersburg, Maryland, USA"
      ],
      "name": "Dmitry I Gabrilovich"
    }
  ],
  "title": "From controversy to opportunity: experts weigh in on myeloid states as determinants in cancer immunotherapy",
  "uid": "fa370a2d-32a2-5cf7-872c-d7f1807dc771"
}